increase font size
Head OfficeClinuvel Pharmaceuticals Limited, Tel: +61 3 9660 4900 |
Swiss OfficeNeuhofstrasse 3D Tel: +41 41 767 4545 |
US Office40 Worth Street, Fax: +1 646 527 7309 |
Clinuvel receives a large number of inquiries every day. For a list of frequently asked questions, including information on projected release dates and trial participation please click here.
For more information on Clinuvel’s program for SCENESSE® in vitiligo, please go to http://www.clinuvel.com/vitiligo.
Buy : 1.86
Sell : 2.05
First : 1.93
Last : 2
High : 2.02
Low : 1.9
ASX: CUV 20 mins delay.
Volume : 34,283 Trades: 38
Last Traded : 21-May-2013 15:53:06
We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...
Read MoreClinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...
Read More
Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...
Read More
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
